CA9 and glioblastoma: CapG (50), non-endocytic co-transport and cytoplasmic translocation (51), DR5 (52), dynamic transformation (53), Glioblastoma (54), CA9/CAIX activity (55), p53–HDM2 disruption (56), mesothelin (57)